Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Thrombin alfa - ZymoGenetics

Drug Profile

Thrombin alfa - ZymoGenetics

Alternative Names: Recombinant thrombin - ZymoGenetics; Recothrom; rhThrombin

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ZymoGenetics
  • Developer Bayer HealthCare; ZymoGenetics
  • Class Antihaemorrhagics; Blood coagulation factors; Serine endopeptidases
  • Mechanism of Action Fibrin stimulants; Serine endopeptidase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Surgical blood loss

Most Recent Events

  • 19 Mar 2018 Baxter International completes the acquisition of thrombin alfa (RECOTHROM) from Mallinckrodt
  • 08 Jan 2018 Baxter International entered into an agreement to acquire thrombin alfa from Mallinckrodt for Surgical blood loss
  • 01 Feb 2016 Mallinckrodt plc acquired the haemostasis portfolio of The Medicines Company
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top